Eriksen, E. F., Lyles, K. W., Colon-Emeric, C. S., Pieper, C. F., Magaziner, J. S., Adachi, J. D., … Mesenbrink, P. (2008). The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial. CALCIFIED TISSUE INTERNATIONAL, 82, S41–S41.

Eriksen, E. F., K. W. Lyles, C. S. Colon-Emeric, C. F. Pieper, J. S. Magaziner, J. D. Adachi, L. Hyldstrup, et al. “The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial.” CALCIFIED TISSUE INTERNATIONAL 82 (January 1, 2008): S41–S41.

Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, et al. The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial. CALCIFIED TISSUE INTERNATIONAL. 2008 Jan 1;82:S41–S41.

Eriksen, E. F., et al. “The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial.” CALCIFIED TISSUE INTERNATIONAL, vol. 82, SPRINGER, Jan. 2008, pp. S41–S41.

Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P. The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial. CALCIFIED TISSUE INTERNATIONAL. SPRINGER; 2008 Jan 1;82:S41–S41.